CAR T-cell Therapy

Gail J. Roboz, MD, a professor of Medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the impact of the FDA approval of tisagenlecleucel (CTL019) in patients with acute lymphoblastic leukemia.

The FDA issued a historic approval of the first chimeric antigen receptor (CAR) T-cell therapy, authorizing the use of tisagenlecleucel (Kymriah) for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse.

Gilead has announced plans to acquire Kite Pharma for $180.00 per share in cash, totaling approximately $11.9 billion.

Shaji Kumar, MD, discusses his ixazomib maintenance trial, the latest FDA activity in myeloma, and the potential of chimeric antigen receptor (CAR) T-cell therapy in the field of myeloma.

Chimeric antigen receptor (CAR) T-cell therapies could spawn a new and lucrative industry in anticancer immunotherapy, resulting in single-infusion treatments costing hundreds of thousands of dollars, and even attracting medical tourism from abroad, where regulatory permissions are likely to come more slowly than in the United States.

Researchers have determined that CD30-specific CAR T cells could be used safely and induce durable complete responses in patients with Hodgkin lymphoma and anaplastic large cell lymphoma.

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses a therapeutic option on the horizon for patients with mantle cell lymphoma (MCL) who are intolerant to ibrutinib (Imbruvica).

Gail Roboz, MD, a professor of Medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the challenges clinicians are facing with chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses the possibility of blending immunotherapy agents with chimeric antigen receptor (CAR) T-cell therapy across lymphoma populations.

Saad Z. Usmani, MD, discusses recent multiple myeloma data, the potential role of CAR T-cell therapy, and what therapeutic advancements the community can expect in the remainder of 2017.

Treatment with CD19 chimeric antigen receptor-modified T-cell therapy induced a high response rate in patients with high-risk, ibrutinib-refractory chronic lymphocytic leukemia.

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses CAR T-cell therapy in head and neck cancer.

Sattva S. Neelapu, MD, discusses the latest results for axicabtagene ciloleucel (KTE-C19) for transplant-ineligible patients with relapsed/refractory non-Hodgkin lymphoma and the CAR T-cell therapy’s potential to be a new standard of care.

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses CAR T-cell therapy for patients with head and neck cancer.

Ezra Cohen, MD, discusses anti–PD-1/PD-L1 combination regimens in HNSCC, the potential for CAR T-cell therapy, and remaining challenges with immunotherapy in the field.

Bajil J. Shah, MD, discusses the significant impact CAR T-cell therapy can have on the treatment landscape for patients with acute lymphoblastic leukemia.

Oncologic Drugs Advisory Committee voted 10-0 today to recommend approval of a biologics license application for tisagenlecleucel (CTL019) for the treatment of patients aged 25 or younger with relapsed/refractory B-cell acute lymphoblastic leukemia.

Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, explains why chimeric antigen receptor (CAR) T-cell therapy has shown the most progress in acute lymphoblastic leukemia (ALL).

Eric Smith, MD, PhD, discusses the response to CD19 CAR T-cell therapy in B-cell ALL.

CTL019, an investigational chimeric antigen receptor T-cell therapy, demonstrated high response rates and a manageable safety profile in pediatric and young adult patients with relapsed and/or refractory acute lymphoblastic leukemia.

Miguel-Angel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, director, Adult Bone Marrow Transplantation Fellowship Program, Memorial Sloan Kettering Cancer Center, discusses the remaining questions with CAR T-cell therapy in hematologic malignancies.

All patients with multiple myeloma in a phase I study showed a response following treatment with an active dose of bb2121, an investigational anti–BCMA CAR T-cell construct.

Investigators reported the characterization of early clinical and serum biomarkers that may identify specific patients with ALL being treated with 19-28z chimeric antigen receptor T cells needing an early intervention to mitigate the development of severe neurotoxicity.

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses CAR T-cell therapy in multiple myeloma.

Jeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the TRANSCEND study, which is exploring the CD19-directed chimeric antigen receptor (CAR) T-cell therapy JCAR017 in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL).

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma.

Concurrent treatment with CTL-119 cell therapy and ibrutinib (Imbruvica) led to complete marrow clearance of leukemic cells in 8 of 9 evaluable patients with heavily pretreated or genetically high-risk chronic lymphocytic leukemia, results of a pilot study showed.

The FDA’s Oncologic Drugs Advisory Committee has scheduled a public hearing to discuss a biologics license application for tisagenlecleucel-T for patients aged 3 to 25 years with relapsed/refractory B-cell acute lymphoblastic leukemia.

Peter Martin, MD, discusses the evolution of treatment and ongoing research for patients with mantle cell lymphoma.

The FDA has granted a priority review to axicabtagene ciloleucel for transplant-ineligible patients with relapsed or refractory non-Hodgkin lymphoma.